
HTG Molecular Diagnostics HTGM
Annual report 2022
added 03-30-2023
HTG Molecular Diagnostics Accounts Payables 2011-2026 | HTGM
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables HTG Molecular Diagnostics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.16 M | 1.65 M | 1.35 M | 1.66 M | 1.85 M | 2.44 M | 762 K | 725 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.44 M | 725 K | 1.45 M |
Quarterly Accounts Payables HTG Molecular Diagnostics
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 710 K | 1.12 M | 1.32 M | 1.65 M | 1.15 M | 1.68 M | 1.35 M | 1.35 M | 1.35 M | 1.35 M | 1.35 M | 1.66 M | 1.66 M | 1.66 M | 1.66 M | 1.85 M | 1.85 M | 1.85 M | 1.85 M | 2.44 M | 2.44 M | 2.44 M | 2.44 M | 762 K | 762 K | 762 K | 762 K | 725 K | 725 K | 725 K | 725 K | 948 K | 948 K | 948 K | 948 K | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 2.44 M | 710 K | 1.37 M |
Accounts Payables of other stocks in the Diagnostics research industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Co-Diagnostics
CODX
|
1.88 M | $ 1.29 | -20.86 % | $ 1.72 M | ||
|
Fulgent Genetics
FLGT
|
18.4 M | $ 15.71 | -2.96 % | $ 475 M | ||
|
Agilent Technologies
A
|
446 M | $ 111.77 | -1.3 % | $ 34 B | ||
|
Castle Biosciences
CSTL
|
18.7 M | $ 19.2 | 1.69 % | $ 557 M | ||
|
Akumin
AKU
|
36.6 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
4.5 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
1.52 M | - | -13.05 % | $ 7.29 M | ||
|
Illumina
ILMN
|
221 M | $ 143.1 | -0.1 % | $ 22.8 B | ||
|
Interpace Biosciences
IDXG
|
983 K | $ 1.8 | - | $ 7.96 M | ||
|
CareDx, Inc
CDNA
|
9.99 M | $ 20.02 | -2.29 % | $ 1.07 B | ||
|
Chembio Diagnostics
CEMI
|
3.34 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
790 K | - | - | $ 9.42 M | ||
|
Lantheus Holdings
LNTH
|
42.9 M | $ 94.21 | -2.55 % | $ 6.36 B | ||
|
Mettler-Toledo International
MTD
|
267 M | $ 1 034.95 | -0.67 % | $ 21.3 B | ||
|
Medpace Holdings
MEDP
|
28.1 M | $ 417.68 | -0.36 % | $ 12 B | ||
|
Global Cord Blood Corporation
CO
|
8.33 M | - | - | $ 399 M | ||
|
Myriad Genetics
MYGN
|
30 M | $ 3.59 | -0.97 % | $ 332 M | ||
|
DermTech
DMTK
|
1.48 M | - | -11.32 % | $ 2.94 M | ||
|
NeoGenomics
NEO
|
23.1 M | $ 8.26 | -1.2 % | $ 1.06 B | ||
|
Charles River Laboratories International
CRL
|
149 M | $ 150.9 | -5.17 % | $ 7.48 B | ||
|
National Research Corporation
NRC
|
1.17 M | $ 18.56 | -1.95 % | $ 415 M | ||
|
Natera
NTRA
|
31.1 M | $ 188.46 | -4.22 % | $ 18.5 B | ||
|
Enzo Biochem
ENZ
|
1.38 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
176 M | - | - | $ 19.8 B | ||
|
Guardant Health
GH
|
54.4 M | $ 95.46 | -3.24 % | $ 12 B | ||
|
Senseonics Holdings
SENS
|
4.06 M | $ 5.76 | -1.12 % | $ 240 M | ||
|
Personalis
PSNL
|
13 M | $ 6.4 | -4.69 % | $ 571 M | ||
|
Heska Corporation
HSKA
|
16.4 M | - | - | $ 1.31 B | ||
|
ICON Public Limited Company
ICLR
|
173 M | $ 115.74 | -1.15 % | $ 9.55 B | ||
|
Soleno Therapeutics
SLNO
|
12.4 M | $ 53.0 | 0.01 % | $ 2.69 B | ||
|
QIAGEN N.V.
QGEN
|
72.7 M | - | - | $ 10.6 B | ||
|
Biomerica
BMRA
|
295 K | $ 2.3 | -4.56 % | $ 5.28 M | ||
|
Laboratory Corporation of America Holdings
LH
|
841 M | $ 251.69 | -0.92 % | $ 20.9 B | ||
|
Thermo Fisher Scientific
TMO
|
3.62 B | $ 438.03 | -2.27 % | $ 165 B | ||
|
Celcuity
CELC
|
6.41 M | $ 137.57 | 2.12 % | $ 6.43 B | ||
|
Twist Bioscience Corporation
TWST
|
11.1 M | $ 49.03 | -7.4 % | $ 2.93 B | ||
|
Neogen Corporation
NEOG
|
79.6 M | $ 8.18 | -3.02 % | $ 1.77 B | ||
|
Quest Diagnostics Incorporated
DGX
|
307 M | $ 187.21 | -0.39 % | $ 20.8 B | ||
|
Waters Corporation
WAT
|
104 M | $ 331.36 | -0.56 % | $ 19.7 B |